NCT05640245Phase 2Completed

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Study sponsor: MoonLake Immunotherapeutics AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-09-05Actual
Enrollment · participants207Actual
Source updated2026-09-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50). After: Measure: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview